olfactory receptor family 5 subfamily B member 21Genealiases: []
Q-omics provides the consensus-scored OR5B21 profile across patient tissues and cancer cell-line models. OR5B21 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OR5B21 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, OR5B21 RNA expression shows 9,150 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUSC, and LSCC as cancer lineages where OR5B21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR5B21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR5B21 survival associations across molecular data types. OR5B21 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR5B21 RNA expression–survival associations across cancer types. High OR5B21 expression shows unfavorable associations in KIRC, STAD, BLCA, GBM and CHOL, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for OR5B21 RNA expression.
This table summarizes OR5B21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR5B21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR5B21 shows lower tumor expression in LUSC and THCA and higher tumor expression in STAD. The LUSC box plot shows higher OR5B21 RNA expression in normal versus tumor tissue (log2 FC = −0.018, t-test p = .014).
This table shows molecular features associated with OR5B21 in patient tissues and cancer cell lines. In patient samples, OR5B21 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, OR5B21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and SKIN.
